Compound W, a 3,3=-diiodothyronine sulfate (T 2 S) cross-reactive material in maternal serum, was found to be useful as a marker for fetal hypothyroidism. In the present report, we explored its biochemical properties and studied its concentrations in cord and in maternal serum obtained from various gestational periods and at term from different continents. Mean W concentrations, expressed as nmol/L T 2 S-equivalent, in maternal serum during gestation showed a moderate increase at 20 -26 wk (1.57 nmol/L) and an accelerated increase to 34 -40 wk (3.59 nmol/L). The mean serum level was relatively low in nonpregnant women (0.17 nmol/L). Compound W levels in cord and maternal serum at term were not significantly different among samples obtained from Taiwan compared with samples from the United States. The mean cord serum "corrected" (by hot acid digestion) concentrations of W were significantly higher than maternal serum concentrations at birth and were also higher in venous than in paired arterial samples, suggesting that the placenta may play a role in its production. We compared a total of 45 iodothyronine analogs by antibody, gel filtration, and HPLC chromatographic studies and found only one compound, N,N-dimethyl- E mploying a sensitive RIA for T 2 S, we found high concentrations in fetal and pregnant serum in humans (1). We further identified that this T 2 S-cross-reactive material is not authentic T 2 S and does not co-chromatograph with synthetic T 2 S on HPLC. Thus, the name Compound W was coined to represent this material in fetal and maternal serum (1). Levels increased with the progression of pregnancy and rapidly peaked before parturition. At delivery, a 20-fold increase in "T 2 S" was found compared with nonpregnant women and returned to baseline within 7-10 d. Serial measurements of serum W in pregnant women have been found to be useful as a noninvasive technique for the diagnosis of fetal hypothyroidism (2,3).The present study was undertaken to determine the normal distribution of elevated Compound W levels in different stages of pregnancy as well as from various geographic areas and correlate between paired maternal and cord blood samples, and to explore its origin and chemical structure. MATERIALS AND METHODS T 2 S RIA. 3,3=-T 2 S and [125 I]T 2 S were prepared by the method of Eelkman-Rooda and co-workers (4,5). T 2 S was further purified and quantitatively recovered by reverse-phase HPLC with a preparative column, as described previously (1,2,4).The T 2 S RIA procedure was a modification of the RIA described previously (1,2). Serum samples (0.2-1.0 mL) were extracted with 2 vol 95% ethanol (final concentration, 63%) before assay. Preliminary experiments showed that the extraction efficiency of T 2 S in serum exceeded 96%. Final T 2 S concentrations were not corrected for recovery. The lower limit of detection of the assay was 3.3 fmol (2 pg), or 33.1 pmol/L in a 300 L ethanol extract of serum. Intra-assay variations were 1.9 -9.1% and interassay variations were 6.0 -19.5%, depending on ...
ABSTRACT:We used novel 3=-monoiodothyronine sulfate (3=-T 1 S) and 3,3=,5-triiodothyroacetic acid sulfate (TriacS) RIAs to characterize sulfation pathways in fetal thyroid hormone metabolism. 3=-T 1 S and TriacS levels were measured in serum samples obtained from fetal (n ϭ 21, 94 -145 d gestational age), newborn (NB, n ϭ 5), and adult sheep (AD, n ϭ 5) as well as from fetuses after total thyroidectomy (Tx), or sham-operated twin fetuses controls, conducted at gestational age 110 -113 d (n ϭ 5). Peak levels (expressed as ng/dL) of both 3=-T 1 S and TriacS occurred at 130 d gestation. These levels in fetuses were higher than those in NB and AD. In Tx fetuses, there was a significant decrease in the mean serum level of 3=-T 1 S, but not TriacS. The decrease in 3=-T 1 S in Tx is similar to that observed for thyroxine sulfate (T 4 S) and 3,3=,5=-triiodothyronine sulfate (rT 3 S), whereas TriacS levels were not altered in the hypothyroid state, similarly to 3,3=,5-triiodothyronine sulfate (T 3 S). These data demonstrate that 3=-T 1 S and TriacS are normal thyroid hormone metabolites in ovine serum and that TriacS is likely derived from T 3 S or from the same precursor(s) as T 3 S. W e have identified the sulfated iodothyronines, thyroxine sulfate (T 4 S), 3,3=,5-triiodothyronine (T 3 S), 3,3=,5=-triiodothyronine sulfate (reverse T 3 S) (rT 3 S), and 3,3=-diiodothyronine sulfate (3,3=-T 2 S), as important thyroid hormone metabolites in ovine and human fetal fluids (1-5). The relatively high concentrations of these sulfated iodothyronines in the developing fetus probably reflect the low type I deiodinase activities observed in fetal tissues (6,7). To further characterize metabolism of the sulfated iodothyronines in ovine fetuses, we developed sensitive and specific 3=-T 1 S and 3,3=-5-triiodothyroacetic acid sulfate (TriacS) RIAs to quantify 3=-T 1 S and TriacS levels in normal and hypothyroid fetal and maternal serum. In previous studies of hypothyroid fetuses, we found significant reductions of mean serum concentrations of T 4 S and rT 3 S, but not T 3 S, suggesting that T 3 , presumably the precursor of T 3 S, was derived from T 3 in tissue. Hypothyroidism may result in a compensatory increase in activity of type II 5=-deiodinase, which tends to maintain tissue T 3 in a relatively normal range (8,9). The present study is to determine whether serum levels of TriacS and/or 3=-T 1 S are reduced in fetal hypothyroidism. MATERIALS AND METHODS 3=-T 1 S and TriacS RIAs. 3=-T 1 S and 3=-[125 I]T 1 S as well as TriacS and [ 125 I]TriacS were prepared by the method of Eelkman-Rooda and co-workers (10,11). 3=-T 1 S and TriacS in 0.025 N NaOH (4 mg/mL) were further purified and quantitatively recovered by reverse-phase HPLC with a preparative column (Biochrom 1010 ODS; Regis, Morton Grove, IL). The products were eluted isocratically with a mixture of acetonitrile and 20 mM ammonium acetate, pH 4.0 (22:78 vol/vol), at a solvent flow of 10 mL/min. 3=-T 1 S and TriacS were recovered with purity Ͼ99%, as assessed by HPLC.The RIA fo...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.